cystic fibrosis market

Cystic fibrosis is a hereditary condition leading to chronic lung infections and eventually decreasing one's ability to breathe. Cystic fibrosis (CF) is a chronic, genetic disorder that affects the respiratory, digestive, and reproductive systems. It primarily impacts the body’s exocrine glands, leading to the production of thick, sticky mucus that can clog airways and trap bacteria, resulting in repeated lung infections, inflammation, and progressive respiratory damage. It is one of the most common life-limiting genetic diseases, particularly among people of Northern European descent.

Individuals with CF, besides the hefty burden of care, face several other unique challenges. Read our newsletter to know more about the diagnostics methods, the standard of care available, therapies in the pipeline, and clinical trials ongoing in the Cystic fibrosis market. 

Gain an idea about the key companies strengthening the pipeline and adding assets, collaborations, mergers and R&D happening in the CF market domain and get a competitive edge. 

Cystic fibrosis is caused by mutations in the CFTR gene (Cystic Fibrosis Transmembrane Conductance Regulator), which is responsible for regulating the movement of salt and water in and out of cells. A defective CFTR protein leads to the buildup of thick mucus in organs such as the lungs and pancreas. CF is inherited in an autosomal recessive manner, meaning a person must inherit two defective copies of the gene (one from each parent) to develop the disease.

Subscribe to our newsletter series for more such insights and analysis.

Get in touch with us for more consulting and business solutions.

Stay in touch!